|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174.10 USD | +0.93% |
|
-3.97% | +13.85% |
Evolution of the Average Target: Biogen Inc.
Evolution of the Target Price: Biogen Inc.
Changes in Analyst Recommendations: Biogen Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +3.49% | |||||
| +5.61% | |||||
| +31.33% | |||||
| +30.22% | |||||
| +12.48% | |||||
| +29.3% | |||||
| +4.41% | |||||
| +20.55% | |||||
| +13.33% | |||||
| - | - | - | |||
| Average | +16.75% | |||||
| Weighted average by Cap. | +17.28% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Morgan Stanley | |
| Wells Fargo Securities | |
| HSBC | |
| Jefferies & Co. | |
| Piper Sandler | |
| Stifel Nicolaus | |
| Mizuho Securities | |
| BMO Capital | |
| Guggenheim | |
| Wedbush | |
| Baird | |
| RBC Capital Markets | |
| Rothschild & Co Redburn | |
| Goldman Sachs | |
| Citigroup | |
| HC Wainwright | |
| TD Cowen | |
| Oppenheimer | |
| Canaccord Genuity | |
| Truist Securities | |
| Argus | |
| Bernstein | |
| Scotiabank | |
| JPMorgan Chase | |
| Redburn Atlantic | |
| BofA Securities | |
| Leerink Partners | |
| Needham & Co. | |
| Barclays | |
| Raymond James | |
| UBS | |
| Atlantic Equities | |
| Cowen | |
| SVB Securities LLC | |
| SVB Leerink | |
| Cantor Fitzgerald | |
| William Blair & Co. | |
| Credit Suisse | |
| DZ Bank |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
- Consensus Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
